Mineralys Therapeutics, Inc.
MLYS
$25.64
-$0.45-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -512.80% | -22.04% | 12.72% | 14.66% | -2.52% |
| Total Depreciation and Amortization | -16.67% | -53.85% | -13.33% | -6.25% | 6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10,441.45% | 78.55% | -68.74% | 48.24% | -10.58% |
| Change in Net Operating Assets | 375.21% | 69.44% | -246.61% | -57.27% | 282.77% |
| Cash from Operations | 17.52% | -4.18% | -31.23% | 4.30% | 33.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -312.12% | 56.57% | 31.25% | -250.99% | 53.83% |
| Cash from Investing | -312.12% | 56.57% | 31.24% | -250.99% | 53.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 504.75% | -74.98% | -67.14% | 2,888.63% | -94.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102,900.00% | 99.67% | -951.72% | 38.30% | -370.00% |
| Cash from Financing | 902.24% | -74.90% | -67.24% | 2,902.62% | -94.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.38% | -34.62% | -138.58% | 283.19% | -224.16% |